Dow Pharmaceutical Sciences
As of the edition of 20 October 2026, Dow Pharmaceutical Sciences runs 8 drugs, 4 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Went quiet | 4 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tretinoin | none listed | 3 |
| Clobetasol propionate | none listed | 2 |
| Halobetasol propionate | none listed | 1 |
| Efinaconazole | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Skin and connective tissue: 9 trials led
- Infections: 3 trials led